"Since 1991, Retina Associates has been a leader in the management of Diseases and Surgery of the Retina and Vitreous and related disorders. We provide state-of-the-art compassionate care to our many patients. Retina Associates is committed to physician education and scientific investigation to advance understanding and treatment of retinal disease. The physicians of Retina Associates are devoted to the care of patients with disorders of the retina and vitreous. We specialize in the diagnosis and medical and surgical treatment of a variety of serious conditions such as macular degeneration, retinal vascular disease including diabetic retinopathy and vein occlusion, retinal detachment, trauma, and cancer."

During the past decade, Retina Associated Ltd conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Associated Ltd" #1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator, "Parexel" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Retina Associated Ltd" are "Central Retinal Vein Occlusion" (1 trials), "Diabetic Retinopathy" (1 trials), "Hemiretinal Vein Occlusion" (1 trials), "Macular Edema" (1 trials) and "Neovascular (Wet) Age-related Macular Degeneration (AMD)" (1 trials). Many other conditions were trialed in "Retina Associated Ltd" in a lesser frequency.

Most popular intervention types in "Retina Associated Ltd" are "Drug" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept" (2 trials), "ABP 938" (1 trials), "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials), "Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)" (1 trials) and "Faricimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Retina Associated Ltd" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Retina Associated Ltd". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Retina Associated Ltd, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Retina Associated Ltd, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".